Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
You may also be interested in...
The biotech company already has a candidate with a tough target in the clinic for COVID-19 and plans to have four to six candidates in the clinic over the next two years following a $273m series C round.
As FDA clears new COVID vaccines, the Regeneron deal is a reminder of the politics of drug pricing. Sen. Sanders touts the agreement, which attaches product price caps to funding for clinical development, and he allows the confirmation effort for the NIH director nominee to proceed.
The companies are all preparing to make available vaccines targeted to Omicron XBB subvariants, with the expectation that demand in the US will be about 50 million to 100 million doses.